| Original language | English (US) |
|---|---|
| Pages (from-to) | 236-237 |
| Number of pages | 2 |
| Journal | Clinical Infectious Diseases |
| Volume | 36 |
| Issue number | 2 |
| DOIs | |
| State | Published - Jan 15 2003 |
Bibliographical note
Funding Information:A randomized trial comparing vanco mycin, linezolid, and TMP-SMZ in the treatment of MRSA infections would be most timely. However, given the probable absence of an interested corporate sponsor, support for such a trial may be needed from nonprofit and governmental entities concerned with health care costs and antimicrobial resistance, including the National Institutes of Health, the Centers for Disease Control and Prevention, the US Food and Drug Administration, the IDSA, and the US Department of Veterans Affairs.
